Healthy Returns: AbbVie is the newest potential weight loss drug market player

1. AbbVie invests $2.2 billion in obesity drug GUB014295 from Gubra. 2. Initial payment of $350 million, with further payments based on milestones. 3. The drug targets amylin, potentially reducing gastrointestinal side effects. 4. Analyst predicts growth synergies with AbbVie's existing inflammatory and aesthetic products. 5. The deal follows Humira's patent expiration, seeking new revenue sources.